Suspension of sales of Reductil®, Ectiva® and Reduxade® in Singapore

Abbott Laboratories (S) Pte Ltd is informing healthcare professionals of the suspension of sales of Reductil®, Ectiva® and Reduxade® from the Singapore market at the request of HSA. HSA's decision to suspend sibutramine took into consideration the results of the SCOUT (Sibutramine Cardiovascular Outcomes) study, the use of sibutramine in the local context and the developments in other international jurisdictions. SCOUT study is an approximately 10,000 patient, six-year study requested by European regulatory authorities as a post-marketing commitment to evaluate cardiovascular safety in high-risk patients. Patients treated with sibutramine experienced a 16% increased risk of a primary outcome event of non-fatal myocardial infarction, non-fatal stroke, resuscitated cardiac arrest, or cardiovascular death compared with placebo-treated patients. This result was attributed to an increased risk of non-fatal myocardial infarction and stroke.